CompletedPhase 1NCT00448253

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

Studying Inhalational anthrax

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Emergent BioSolutions
Principal Investigator: Alan S Marion, MD, PhD
MDS Pharma Services
Intervention: NP-015(biological)
Enrollment: 92 target
Eligibility: 18-55 years · All sexes
Timeline: 2007 – 2008

Study locations (1)

MDS Pharma Services, Lincoln, Nebraska, United States

Collaborators

Department of Health and Human Services

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00448253 on ClinicalTrials.gov

← Back to all trials